U.S. markets closed
  • S&P Futures

    3,840.00
    +5.75 (+0.15%)
     
  • Dow Futures

    30,950.00
    +41.00 (+0.13%)
     
  • Nasdaq Futures

    13,389.75
    +28.25 (+0.21%)
     
  • Russell 2000 Futures

    2,163.30
    -0.70 (-0.03%)
     
  • Crude Oil

    52.20
    -0.07 (-0.13%)
     
  • Gold

    1,856.50
    +0.30 (+0.02%)
     
  • Silver

    25.62
    +0.06 (+0.25%)
     
  • EUR/USD

    1.2170
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.0910
    -0.0180 (-1.62%)
     
  • Vix

    21.91
    +0.59 (+2.77%)
     
  • GBP/USD

    1.3685
    -0.0045 (-0.33%)
     
  • USD/JPY

    103.8000
    +0.2950 (+0.29%)
     
  • BTC-USD

    32,164.62
    +370.29 (+1.16%)
     
  • CMC Crypto 200

    651.44
    +41.45 (+6.79%)
     
  • FTSE 100

    6,695.07
    -20.35 (-0.30%)
     
  • Nikkei 225

    28,631.45
    -125.45 (-0.44%)
     

Curis to Present at B. Riley Securities Virtual Oncology Investor Conference

·2 min read

LEXINGTON, Mass., Jan. 14, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on Thursday, January 21, 2021 at 11:00 am ET.

(PRNewsfoto/Curis, Inc.)
(PRNewsfoto/Curis, Inc.)

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website for 90 days following the event.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin's lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-to-present-at-b-riley-securities-virtual-oncology-investor-conference-301208244.html

SOURCE Curis, Inc.